A phase 2 pivotal of 150 patients open label study will not cost that much. Its almost a guarantee the trial will be successful. By that time the market cap will be well above 1B, making it very easy to raise cash to run those other trails you talk about. They can partner the EU and the world right, but IMO its important to keep US to themselves. Especially since 543 is the drug of last resort, it will not take that much money to market it. I bet you 534 will not go for the solid tumour indication since the blood concentration can not be high enough without the pancreatitis AEs.
Market Data 
Markets 
AI
